Izotropic Shares AGM Outcome

## Izotropic Streamlines Shareholder Governance with Quorum Reduction, Board Appointments

**Vancouver, BC & Sacramento, CA – December 31, 2025** – Izotropic Corporation, a medical device company focused on innovative breast cancer screening and diagnostic technologies, has announced the outcomes of its Annual General and Special Meeting held on December 29, 2025. The meeting saw shareholders approve key resolutions aimed at enhancing operational efficiency and governance, including the election of a new five-member board of directors and a significant reduction in the quorum requirement for shareholder meetings.

Shareholders overwhelmingly supported the slate of nominees for the upcoming year, solidifying a five-member board designed to guide the company’s strategic initiatives. This move comes as Izotropic continues to advance its commercialization efforts for its advanced imaging-based products, which promise more accurate detection and diagnosis of breast cancers. The company views a well-structured board as critical for navigating the complex regulatory and market landscapes inherent in the medical technology sector.

In a move that directly addresses logistical challenges faced by public companies in the current environment, Izotropic shareholders also approved an amendment to the company’s by-laws. The quorum requirement for shareholder meetings has been reduced from 20% to a minimum of 1% of the issued voting shares. This adjustment is a direct response to persistent mail delays, disruptions in postal services, and the increasing use of self-managed trading platforms by shareholders, all of which have historically hindered the ability to achieve the previous quorum threshold.

This reduction, while lowering the barrier to convening meetings, maintains the principle that decisions will still require majority approval from those shares represented. This aims to balance the need for accessible shareholder participation with the necessity of making timely corporate decisions, particularly crucial for a company operating in a rapidly evolving technological field like medical imaging.

Furthermore, Dale Matheson Carr-Hilton LaBonte LLP was ratified for re-appointment as the company’s auditor. This continuity in audit services provides a sense of stability and ensures ongoing adherence to rigorous financial reporting standards, a non-negotiable aspect for companies seeking investment and partnerships in the capital markets.

The strategic significance of these decisions extends beyond mere procedural adjustments. For a company like Izotropic, which is at the forefront of developing sophisticated medical imaging technology such as its IzoView system (though note that IzoView has not yet received regulatory approval for sale), efficient corporate governance is paramount. The ability to convene shareholder meetings without undue delay facilitates quicker decision-making on crucial matters, including potential strategic alliances, funding rounds, and product development milestones.

From a technological and business perspective, the reduction in quorum can be viewed as an acknowledgment of the evolving nature of shareholder engagement in the digital age. While some might express concerns about the potential for key decisions to be made with a smaller percentage of the shareholder base represented, the company’s emphasis on retaining majority vote requirements mitigates this risk. The focus shifts from the *quantity* of shares present to the *quality* of consensus achieved for each resolution.

Izotropic’s commitment to transparency and shareholder participation remains a key tenet. The company has actively sought to inform its shareholders about these changes and the rationale behind them, aiming to foster a collaborative environment. As Izotropic continues to navigate the path toward bringing its innovative breast cancer technologies to market, these governance enhancements are designed to support its growth trajectory and its mission to improve patient outcomes through advanced imaging solutions.

The company expressed gratitude to its shareholders for their active participation and continued support, recognizing their role in shaping the company’s future.